Launch targets $16 billion SGLT-2 inhibitor market that serves 33 million type II diabetics in the US, many of whom are uninsured and underinsured and whose out-of-pocket costs exceed Brenzavvy's cash price
Proprietary EinsteinRx™ artificial intelligence pharmacy platform empowers the 6,500+ pharmacies in the Wellgistics Pharmacy Network to educate patients and providers on the advantages of Brenzavvy vs. Jardiance® and other SGLT-2 inhibitors
Reduced out-of-pocket costs for patients, paired with a patient-education revenue opportunity for pharmacists, are designed to support broader market access to Brenzavvy and enhance the overall care experience
Launch establishes a new model for next-generation reformulated drugs that offer patient-specific product advantages compared with entrenched market leaders
The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have access to controlled substances for legitimate medical use.
Today, the evidence shows the opposite: DEA officials laundering cartel money, DEA lawyers defending unconstitutional judicial processes, DEA executives cycling into industry roles they once regulated and DEA policies obstructing legitimate FDA authorized medical research.
Read More
Initial development completed at New Rise Reno 2, advancing XCF's second SAF production facility and positioning construction to begin in 2026.
$300 million planned investment will double XCF's total SAF production capacity to ~80 million gallons annually, positioning New Rise Reno as a major U.S. SAF production center.
Global demand accelerates as mandates tighten, creating one of the strongest growth opportunities in renewable fuels - one that XCF's modular SAF platform is positioned to capture.
Chief Scientific Officer of Pace® Life Sciences Joins Industry Leaders at Advancing Drug Development Forum (ADDF) to Collaborate on Technologies for Non-Traditional Molecules
Read More
